'AI Scientist' Suggests Combinations of Widely Available Non-Cancer Drugs can Kill Cancer Cells

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence - could also be effective at treating cancer, a promising new approach to drug discovery.

The research team, led by the University of Cambridge, used the GPT-4 large language model (LLM) to identify hidden patterns buried in the mountains of scientific literature to identify potential new cancer drugs.

To test their approach, the researchers prompted GPT-4 to identify potential new drug combinations that could have a significant impact on a breast cancer cell line commonly used in medical research. They instructed it to avoid standard cancer drugs, identify drugs that would attack cancer cells while not harming healthy cells, and prioritise drugs that were affordable and approved by regulators.

The drug combinations suggested by GPT-4 were then tested by human scientists, both in combination and individually, to measure their effectiveness against breast cancer cells.

In the first lab-based test, three of the 12 drug combinations suggested by GPT-4 worked better than current breast cancer drugs. The LLM then learned from these tests and suggested a further four combinations, three of which also showed promising results.

The results, reported in the Journal of the Royal Society Interface, represent the first instance of a closed-loop system where experimental results guided an LLM, and LLM outputs – interpreted by human scientists – guided further experiments. The researchers say that tools such as LLMs are not replacement for scientists, but could instead be supervised AI researchers, with the ability to originate, adapt and accelerate discovery in areas like cancer research.

Often, LLMs such as GPT-4 return results that aren’t true, known as hallucinations. But in scientific research, hallucinations can sometimes be a benefit, if they lead to new ideas that are worth testing.

"Supervised LLMs offer a scalable, imaginative layer of scientific exploration, and can help us as human scientists explore new paths that we hadn’t thought of before," said Professor Ross King from Cambridge’s Department of Chemical Engineering and Biotechnology, who led the research. "This can be useful in areas such as drug discovery, where there are many thousands of compounds to search through."

Based on the prompts provided by the human scientists, GPT-4 selected drugs based on the interplay between biological reasoning and hidden patterns in the scientific literature.

"This is not automation replacing scientists, but a new kind of collaboration," said co-author Dr Hector Zenil from King's College London. "Guided by expert prompts and experimental feedback, the AI functioned like a tireless research partner - rapidly navigating an immense hypothesis space and proposing ideas that would take humans alone far longer to reach."

The hallucinations - normally viewed as flaws - became a feature, generating unconventional combinations worth testing and validating in the lab. The human scientists inspected the mechanistic reasons the LLM found to suggest these combinations in the first place, feeding the system back and forth in multiple iterations.

By exploring subtle synergies and overlooked pathways, GPT-4 helped identify six promising drug pairs, all tested through lab experiments. Among the combinations, simvastatin (commonly used to lower cholesterol) and disulfiram (used in alcohol dependence) stood out against breast cancer cells. Some of these combinations show potential for further research in therapeutic repurposing.

These drugs, while not traditionally associated with cancer care, could be potential cancer treatments, although they would first have to go through extensive clinical trials.

"This study demonstrates how AI can be woven directly into the iterative loop of scientific discovery, enabling adaptive, data-informed hypothesis generation and validation in real time," said Zenil.

"The capacity of supervised LLMs to propose hypotheses across disciplines, incorporate prior results, and collaborate across iterations marks a new frontier in scientific research," said King. "An AI scientist is no longer a metaphor without experimental validation: it can now be a collaborator in the scientific process."

The research was supported in part by the Alice Wallenberg Foundation and the UK Engineering and Physical Sciences Research Council (EPSRC).

Abdel-Rehim A, Zenil H, Orhobor O, Fisher M, Collins RJ, Bourne E, Fearnley GW, Tate E, Smith HX, Soldatova LN, King R.
Scientific hypothesis generation by large language models: laboratory validation in breast cancer treatment.
J R Soc Interface. 2025 Jun;22(227):20240674. doi: 10.1098/rsif.2024.0674

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

Northern Ireland Completes Nationwide Ro…

Go-lives at Western and Southern health and social care trusts mean every pathology service is using the same laboratory information management system; improving efficiency and quality. An ambitious technology project to...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...

Groundbreaking TACIT Algorithm Offers Ne…

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment...

The Many Ways that AI Enters Rheumatolog…

High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in systemic sclerosis (SSc). But AI-assisted interpretation has the potential...